China Clinical Trials Market

ID: MRFR/MED/48511-HCR 200 Pages Rahul Gotadki Last Updated: September 17, 2026
China Clinical Trials Market Research Report: Size, Share, Trend Analysis By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Therapeutic Area (Oncology, Cardiology, Neurology, Infectious Diseases, Endocrinology) and By End Use (Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations) - Growth Outlook & Industry Forecast 2025 To 2035
China Clinical Trials Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)4.42%
2024 Market Size$ 3,958.8 Million
2025 Market Size$ 4,133.78 Million
2035 Market Size$ 6,371.5 Million
Key Players
Covance
IQVIA
PPD
Charles River Laboratories
Syneos Health
Medpace
Trends
  • Increased Investment in Biotechnology
  • Regulatory Reforms and Streamlining Processes
  • Growing Patient Recruitment Strategies
Opportunities
  • Rising Demand for Innovative Therapies
  • Expansion of International Collaborations
  • Increasing Focus on Personalized Medicine
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Food, Beverages & Nutrition, BY Phase (USD Million)
      1. 4.1.1 Phase I
      2. 4.1.2 Phase II
      3. 4.1.3 Phase III
      4. 4.1.4 Phase IV
    2. 4.2 Food, Beverages & Nutrition, BY Study Design (USD Million)
      1. 4.2.1 Interventional
      2. 4.2.2 Observational
      3. 4.2.3 Expanded Access
    3. 4.3 Food, Beverages & Nutrition, BY Therapeutic Area (USD Million)
      1. 4.3.1 Oncology
      2. 4.3.2 Cardiology
      3. 4.3.3 Neurology
      4. 4.3.4 Infectious Diseases
      5. 4.3.5 Endocrinology
    4. 4.4 Food, Beverages & Nutrition, BY End Use (USD Million)
      1. 4.4.1 Pharmaceutical Companies
      2. 4.4.2 Biotechnology Companies
      3. 4.4.3 Contract Research Organizations
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Covance (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 IQVIA (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 PPD (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Charles River Laboratories (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Syneos Health (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Medpace (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Parexel International (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Wuxi AppTec (CN)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 CHINA MARKET ANALYSIS BY PHASE
    3. 6.3 CHINA MARKET ANALYSIS BY STUDY DESIGN
    4. 6.4 CHINA MARKET ANALYSIS BY THERAPEUTIC AREA
    5. 6.5 CHINA MARKET ANALYSIS BY END USE
    6. 6.6 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
    9. 6.9 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
    11. 6.11 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
    12. 6.12 FOOD, BEVERAGES & NUTRITION, BY PHASE, 2024 (% SHARE)
    13. 6.13 FOOD, BEVERAGES & NUTRITION, BY PHASE, 2024 TO 2035 (USD Million)
    14. 6.14 FOOD, BEVERAGES & NUTRITION, BY STUDY DESIGN, 2024 (% SHARE)
    15. 6.15 FOOD, BEVERAGES & NUTRITION, BY STUDY DESIGN, 2024 TO 2035 (USD Million)
    16. 6.16 FOOD, BEVERAGES & NUTRITION, BY THERAPEUTIC AREA, 2024 (% SHARE)
    17. 6.17 FOOD, BEVERAGES & NUTRITION, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Million)
    18. 6.18 FOOD, BEVERAGES & NUTRITION, BY END USE, 2024 (% SHARE)
    19. 6.19 FOOD, BEVERAGES & NUTRITION, BY END USE, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 China MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY PHASE, 2025-2035 (USD Million)
      2. 7.2.2 BY STUDY DESIGN, 2025-2035 (USD Million)
      3. 7.2.3 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
      4. 7.2.4 BY END USE, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

China Clinical Trials Market Segmentation

China Clinical Trials Market By Phase (USD Million, 2025-2035)

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

China Clinical Trials Market By Study Design (USD Million, 2025-2035)

  • Interventional
  • Observational
  • Expanded Access

China Clinical Trials Market By Therapeutic Area (USD Million, 2025-2035)

  • Oncology
  • Cardiology
  • Neurology
  • Infectious Diseases
  • Endocrinology

China Clinical Trials Market By End Use (USD Million, 2025-2035)

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Contract Research Organizations

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.